By using our site you accept the terms of our cookie policy

Search

Nuclear Imaging Market Worth $2.2 Billion by 2020 for PET & SPECT Equipment Industry

May 5, 2015

Image

Market Research Report "MediPoint: Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts" says Japan and China will present the greatest opportunities for growth, with respective market shares increasing by 75% and almost 100% during the forecasted period.

Complete report on the nuclear imaging market of PET and SPECT equipments spread across 318 pages providing 11 product profiles, 14 company profiles, 91 tables and 42 figures is available at http://www.rnrmarketresearch.com/medipoint-nuclear-imaging-pet-and-spect-equipment-global-analysis-and-market-forecasts-market-report.html

This nuclear imaging market report on PET and SPECT equipments states, that, while the US market will remain steady at around $1.15 billion throughout the forecast period, the country will see its global share fall from 69% in 2013 to 53% by 2020. Meanwhile, the Asia-Pacific (APAC) region will see its share rise from 16% to 29% over the same time frame. The research examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report.

The SPECT and SPECT/CT market is a bigger market than the PET, PET/CT and PET/MRI, because the instruments have been in longer use, are cheaper, and have become the common technique for a wide range of indications. Physicians believe more and more SPECT procedures will be replaced by PET procedures. New developments in hybrid nuclear imaging promise to further increase the utility of hybrid nuclear imaging, while significantly improving patient cost-savings and safety, through reduced need for repeat examinations. This report focuses on the current and future industry trends within the nuclear medicine market, as well as discussing the promising pipeline products, and assessing the competitive landscape.

Contact Us

+44 (0) 203 725 6847